Previous 10 | Next 10 |
Pfizer (NYSE: PFE) recently reported fourth-quarter earnings that missed expectations on the top and bottom line. As a result, a jumpy stock market knocked a few percentage points off the stock price. Despite missing consensus forecasts, Pfizer stock looks like a perfect fit for dividend po...
As fears of a global pandemic continue to grip stock markets and crude oil, not even the biotechnology sector ( IBB ) could escape the wrath with IBB declining more than 6% from year-to-date highs. Indeed, although a handful of biotech names such as VIR which are developing vaccines for the...
The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as wel...
Pharmaceutical giant Pfizer (NYSE: PFE) reported fourth-quarter results Tuesday that beat expectations for revenue, but missed on the bottom line. That miss, combined with weak profit guidance, helped propel shares lower. The stock was trading down by more than 5% as of 3 p....
Relmada Therapeutics (NASDAQ: RLMD ) initiated with Buy rating and $75 (73% upside) price target at Jefferies. More news on: Relmada Therapeutics, Inc., Biogen Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Shareholders of drugmaker Mylan (NASDAQ: MYL) are off to a good start this year, with an 8.4% gain after last year's 27% loss. The market may be thinking of the company's planned combination with Pfizer 's Upjohn business, which focuses on off-patent branded drugs and generics. The dea...
So far, stock market tailwinds because of end of year bonuses, retirement plan contributions, and institutional re-positioning have offset data suggesting the market is overbought. However, a 3% to 5% correction is getting more likely as the rally broadens out (excluding energy), suggesting in...
Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...
Pfizer (NYSE: PFE) will provide patients of Roman, a men's health subsidiary of the privately held digital health company Ro, with the only Pfizer-authorized generic version of Viagra, a blockbuster erectile dysfunction treatment. IMAGE SOURCE: GETTY IMAGES. Under the deal, Pfizer's U...
On some levels, Rigel Pharmaceuticals (NASDAQ: RIGL) and Momenta Pharmaceuticals (NASDAQ: MNTA) are complete opposites. Rigel, based in South San Francisco, focuses on small molecule drugs while Momenta, headquartered in Cambridge, Massachusetts, tackles disease using large molecules cal...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...